NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer
Cancer · 2024
DOI: 10.1002/cncr.35151 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer, 2024. Verfasst von Bobbie J Rimel und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynecologic Oncology, Cedars-Sinai Medical Center, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Antineoplastic Agents, Endometrial Neoplasms, Indoles. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NRG Oncology.
Abstract (Originalsprache)
Purpose
This paper reports the efficacy of the poly (ADP‐ribose) polymerase inhibitor olaparib alone and in combination with the antiangiogenesis agent cediranib compared with cediranib alone in patients with advanced endometrial cancer.
Methods
This was open‐label, randomized, phase 2 trial (NCT03660826). Eligible patients had recurrent endometrial cancer, received at least one (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gynecologic Oncology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
- Clinical Trials Development Division, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
- University of Iowa Hospitals & Clinics, Iowa City, Iowa, USA.
- University of Oklahoma Health Sciences Center, Mercy Hospital Gynecologic Oncology, Oklahoma City, Oklahoma, USA.
- Minnesota Oncology, Coon Rapids, Minnesota, USA.
- St. Luke's Cancer Institute, Boise, Idaho, USA.
ORCID-Profile: Bobbie J Rimel, Floor Backes, Helen MacKay
Förderung
- NCI NIH HHS
- NRG Oncology
Zitieren
APA
Rimel, B. J., Enserro, D., Bender, D. P., Jackson, C. G., Tan, A., Alluri, N., Borowsky, M., Moroney, J., Hendrickson, A. W., Backes, F., Swisher, E., Powell, M., & MacKay, H. (2024). NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer. https://doi.org/10.1002/cncr.35151
Vancouver
Rimel BJ, Enserro D, Bender DP, Jackson CG, Tan A, Alluri N, et al. NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer. 2024. doi:10.1002/cncr.35151
BibTeX
@article{Rimel2024,
author = {Rimel, Bobbie J and Enserro, Danielle and Bender, David P and Jackson, Camille Gunderson and Tan, Annie and Alluri, Nitya and Borowsky, Mark and Moroney, John and Hendrickson, Andrea Wahner and Backes, Floor and Swisher, Elizabeth and Powell, Matthew and MacKay, Helen},
title = {NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer},
journal = {Cancer},
year = {2024},
doi = {10.1002/cncr.35151}
}
EUVIMED